NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/28/2026
Back to search
Official data from USPTO
ASCENTAGE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
04/28/2026
Trademark type
Combined
Nice classes
5
Filing date
03/31/2025
Registration date
04/28/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/28/2026
Last transaction
04/28/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
3
Owner type
99
Owner location
JIANGSU, CN
Examiner
SCHLEGELMILCH, JONATHON A
Law office
L80
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the word Ascentage in a stylized font with two arc-shaped lines appearing above and underneath the first "A", and the center line of the first "A" appearing as a diagonal line extending above the letters "sce" of Ascentage.
Holders and representatives
Holders
ASCENTAGE PHARMA (SUZHOU) CO., LTD.
Representatives
Kathryn E. Smith WOOD HERRON & EVANS LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Chemical preparations for medical purposesfor use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; drugs sold in bulkfor use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; biochemical medicines for use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; medicines for human purposes for use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; pharmaceutical preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compoundsnext-generation kinase inhibitors and senolytic drugs; biological preparations for medical purposesbiological preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; chemical preparations for pharmaceutical purposesfor use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; radioactive substances for medical purposes; gases for medical purposesnitric oxide for medical purposes; chemical conductors for electrocardiograph electrodes; semen for artificial insemination; disinfectants; solutions for contact lenses; media for bacteriological cultures for medical purposes; medicated sweets; dietetic preparations adapted for medical purposes; depuratives for the body; diagnostic preparations for veterinary purposes; pesticides; sanitary napkins; cotton for medical purposes; dental abrasives; diapers for pets
Publications
History of USPTO decisions and trademark events.
23 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/28/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/10/2026
PUBO
PUBLISHED FOR OPPOSITION
03/10/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/04/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/12/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/11/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/11/2026
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
02/11/2026
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
01/12/2026
GNSL
LETTER OF SUSPENSION E-MAILED
01/12/2026
CNSL
SUSPENSION LETTER WRITTEN
01/12/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/05/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/05/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/05/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/10/2025
GNRT
NON-FINAL ACTION E-MAILED
09/10/2025
CNRT
NON-FINAL ACTION WRITTEN
09/10/2025
DOCK
ASSIGNED TO EXAMINER
08/28/2025
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
08/14/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/14/2025
MAFR
APPLICATION FILING RECEIPT MAILED
03/31/2025
NWAP
NEW APPLICATION ENTERED
03/31/2025
Continuous trademark protection
Get notified about every new filing that threatens ASCENTAGE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.